Scott Hanan, MD
Surgical Oncology · New York, NYNPI 1487649372
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (41.0%), education and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 75.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $6,027 and has fallen 98.6% since, to $84 in 2025. Among surgical oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $325.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- Globus Medical$3K
- Medtronic$630
- Northgate Technologies, Inc.$250
- KARL Storz Endoscopy-america$106
- Smith+Nephew$49
- plus $50 from 2 others
What the payments were for
- Speaking & faculty fees$2502%
- Travel & lodging$3,73726%
- Food & beverage$6595%
- Education$4,00027%
- Other$6,00041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $11,024 |
| Globus Medical | 18 | $2,538 |
| Medtronic(2 entities) | 4 | $630 |
| Northgate Technologies, Inc. | 1 | $250 |
| KARL Storz Endoscopy-america | 1 | $106 |
| Smith+Nephew | 1 | $49 |
| BD | 1 | $33 |
| Mimedx Group, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$10,743
- ALIF$2,234
- Micra$596
How this compares
$14,646 in reported general payments places this provider in the 90th percentile of 173 surgical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clindamycin Phosphate | 13 | $244 |
| Oxycodone Hcl | 78 | $242 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in New York
- Sheldon FeldmanNew York$97K
- Kepal PatelNew York$94K
- George PlitasNew York$39K
- James ParkNew York$28K
- Michael LoweNew York$20K
- Marcovalerio MelisNew York$12K
- Kevin SoaresNew York$10K
- Jennifer CracchioloNew York$9K
- Bert PetersenNew York$7K
- Paul SchmidtNew York$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.